Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide

Jonathan Pinkney
Thomas Fox
Lakshminarayan Ranganath
1Department of Diabetes and Endocrinology, Peninsula College of Medicine and Dentistry, Plymouth, United Kingdom; 2Department of Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Liverpool, United Kingdom

Abstract: Failure of secretion of the incretin hormone glucagon-like peptide-1 (GLP-1) plays a prominent role in type 2 diabetes, and restoration of GLP-1 action is an important therapeutic objective. Although the short duration of action of GLP-1 renders it unsuited to therapeutic use, 2 long-acting GLP-1 receptor agonists, exenatide and liraglutide, represent a significant advance in treatment. In controlled trials, both produce short-term glucose-lowering effects, with the reduction in hemoglobin A1c of up to 1.3%. These responses are often superior to those observed with additional oral agents. However, unlike sulfonylureas, thiazolidinediones, or insulin, all of which lead to significant weight gain, GLP-1 receptor agonists uniquely result in long-term weight loss of around 5 kg, and higher doses may enhance this further. Reduction in blood pressure of 2–7 mm Hg also has been observed. Both drugs produce transient mild gastrointestinal side effects; although mild hypoglycemia can occur, this is usually in combination with other hypoglycemic therapies. However, serious hypoglycemia and acute pancreatitis are rare. The once-daily dosage of liraglutide makes it more convenient than twice-daily dosage of prandial exenatide, and a superior glucose-lowering effect was observed in the only head-to-head comparison reported so far. Besides cost, these considerations currently favor liraglutide over exenatide. Further studies are needed to confirm long-term safety, and most importantly, that short-term benefits translate into long-term reductions of diabetes-related cardiovascular events and other complications.

Keywords: diabetes, weight loss, glycemic control, blood pressure

Overview of GLP-1

The hormones secreted from the gut endocrine cells play key roles in the control of energy balance by regulating the assimilation, storage, and metabolism of nutrients. Disruption of these endocrine cells disturbs the normal control of body weight and insulin production and contributes to the development of type 2 diabetes (T2D). Two of these hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulino tropic polypeptide (GIP), are known as incretin hormones due to their ability to increase the β-cell insulin response to ingested glucose.1,2 It has been estimated that the incretin effect accounts for as much as 70% of insulin secretion in healthy persons and half of that in patients with T2D.3 Importantly, the incretin effect, in particular, postprandial production of GLP-1, is significantly impaired in patients with T2D.5

GLP-1 has been considered to be more important than GIP. GLP-1 is derived from the proglucagon gene expressed in pancreatic islet cells, L-cells of the small and large intestine, and neurons in the brainstem. Both transcription and translation are under the control of multiple tissue-specific regulatory mechanisms.6 The actions
of GLP-1 are mediated through G-protein-coupled receptors widely expressed in pancreatic islet β cells throughout the gastrointestinal tract, kidney, lung, heart, major blood vessels, adipose tissue, on gastric vagal afferents, and in many brain regions. GLP-1 suppresses food intake through a pathway involving vagal afferent fibers, signaling to regions of the brainstem and hypothalamus. Thus, sustained administration of GLP-1 leads to weight loss in animals. Although the insulin response to GIP is impaired in T2D, the response to GLP-1 is preserved, making GLP-1 a feasible treatment. Furthermore, the administration of intravenous GLP-1 suppresses hyperglucagonemia in healthy subjects and normalizes blood glucose levels in patients with T2D. Gastric emptying is also delayed by GLP-1, and the increase in postprandial glucose is attenuated. Satiety is also increased, and the overall energy intake is reduced by treatment with GLP-1. Thus, GLP-1 has many useful effects that make it appealing as a potential treatment of T2D.

The principal problem with GLP-1 as a therapeutic agent is that the N-terminal is rapidly cleaved by the enzyme dipeptidyl peptidase-IV (DPP-IV) resulting in the generation of inactive GLP-1-(9-36) amide. As a result, the half-life of GLP-1 after secretion is around 1.5 minutes, which is insufficient for a convenient frequency of injections to restore serum GLP-1 levels in humans. Therefore, a series of long-acting receptor agonists of GLP-1 have been developed, and this class of drug is now making a major impact in the treatment of T2D. This article compares the clinical pharmacology and therapeutics of the 2 currently available GLP-1 receptor agonists, exenatide and liraglutide, and comments on the choice between these drugs in clinical practice.

Clinical pharmacology

Exenatide

Exenatide is a synthetic version of exendin-4, a molecule that is found in the saliva of the Gila monster. Exendin-4 has been found to have GLP-mimetic actions as an insulinotropic agent. Exenatide is a larger peptide than GLP-1, at 39 rather than 20 amino acids, and shares 53% homology. Owing to a substitution of glycine for alanine at position 8, exenatide is resistant to degradation by DPP-IV. Exenatide binds more avidly to the GLP-1 receptor in humans than does GLP-1. These pharmacological differences make exenatide have a much longer half-life compared with GLP-1 (3.4–4 hours vs 1.5 minutes). Exenatide is detectable within the plasma 15 minutes after subcutaneous injection and remains detectable for up to 15 hours. As a peptide, exenatide is degraded rapidly in the stomach and, therefore, requires parenteral administration. Unlike GLP-1, exenatide undergoes renal excretion, and as a result, it has not been licensed for use in patients with estimated glomerular flow rate of <30 mL/min. The administration of exenatide up to 1 hour before meals results in lower glucose levels postprandially than administration after a meal. These factors determine the recommended dosing regimen of exenatide, which is twice daily, up to 1 hour before meals, at least 6 hours apart.

Liraglutide

Liraglutide is 97% homologous with human GLP-1, but differs from native human GLP-1 by possessing an Arg-to-Lys substitution and a C16 fatty acid moiety bridged by glutamate at Lys. These changes confer resistance to enzymatic cleavage while the fatty acid moiety binds noncovalently to albumin, thereby lowering the absorption from the injection site and also reducing renal clearance. Thus, liraglutide reaches peak plasma concentrations after 10–14 hours and has a half-life of 11–13 hours, making it suitable for once-daily administration irrespective of meal times. A property of GLP-1 receptor agonists that makes them attractive as therapeutic agents in diabetes is that insulin secretion ceases when euglycemia is achieved, thereby minimizing the risk of hypoglycemia. Renal impairment has been found to have little effect on the pharmacokinetics of liraglutide, suggesting that the drug is likely to be safe to use in patients with kidney disease.

Treatment of diabetes

Exenatide

Initial trials found that 1 month of treatment with exenatide by subcutaneous injection twice daily significantly reduced plasma glucose levels and consequently hemoglobin A1c (HbA1c) in patients with T2D. The beneficial effects of exenatide on glycemic control were confirmed by a 4-week, blinded, placebo-controlled trial, in which exenatide reduced HbA1c by 0.8%–1.1% from baseline. Insulin secretion, as determined from the homeostasis model assessment, showed an increase of 50%–100% in those treated with exenatide at 14 and 28 days compared with baseline. Early trials did not demonstrate significant changes in weight and only encountered mild gastrointestinal side effects.

A series of good-quality, randomized, double-blinded, placebo-controlled phase III clinical trials have assessed the efficacy and tolerability of exenatide. The trials include combinations of exenatide or placebo with sulfonylurea, metformin, and metformin plus sulfonylurea. These studies...
are well designed but tend to suffer from relatively high drop-out rates. The primary end points were HbA$_{1c}$ and safety, and the secondary end points were fasting plasma glucose level, weight, and adverse events.

A 30-week trial of exenatide at doses of 5 and 10 µg daily vs placebo added to existing sulfonylurea therapy in patients with type 2 diabetes mellitus found a reduction in HbA$_{1c}$ of 0.46% and 0.86%, respectively, compared with a 0.12% increase in HbA$_{1c}$ in the placebo group. Fasting plasma glucose was only significantly reduced in the 10 µg exenatide group. Similar effects on HbA$_{1c}$ were observed when exenatide was added to metformin monotherapy. After 30 weeks of treatment with metformin and exenatide at the 5 or 10 µg doses, HbA$_{1c}$ decreased by 0.4% and 0.78%, respectively, compared with a small increase of 0.08% in HbA$_{1c}$ in the placebo group. Again, effects on fasting plasma glucose level were modest, reflecting the glucose-dependent insulinotropic effect of exenatide, reducing postprandial glucose more effectively than fasting glucose. In combination with metformin and sulfonylurea, exenatide 5 µg reduced HbA$_{1c}$ by 0.6% and 10 µg reduced HbA$_{1c}$ by 0.8% after 30 weeks.

More recent studies of a design comparable to the aforementioned ones investigated the addition of exenatide or placebo to a combination of thiazolidinedione (pioglitazone or rosiglitazone) with or without metformin. In a 16-week study, HbA$_{1c}$ was reduced by 0.98% compared with placebo. In a 24-week study, exenatide 5 and 10 µg twice daily or placebo was given to drug-naive patients with T2D suboptimally controlled by diet and exercise. Both the 5 and 10 µg doses of exenatide improved HbA$_{1c}$ by 0.7% and 0.9%, respectively, in addition to improvements in fasting and postprandial plasma glucose levels. A recent open-label study randomized patients to exenatide, rosiglitazone, or the combination of both and found the greatest reduction in HbA$_{1c}$ of -1.3% in the combination therapy group. The combination also produced improvements in both insulin sensitivity and first- and second-phase insulin secretion.

The comparative efficacies of exenatide and insulin have been investigated in 2 open-label trials. In a 26-week study, patients with suboptimally controlled T2D on metformin and sulfonylurea were assigned to receive 10 µg exenatide or once-daily insulin glargine titrated to fasting blood glucose of <5.6 mmol/L. In both groups, HbA$_{1c}$ was reduced by 1.1%. In a 16-week duration crossover study of exenatide 10 µg administered twice-daily vs once-daily insulin glargine, equivalent reductions of 1.36% were observed in HbA$_{1c}$. Similar effects were found when exenatide 10 µg twice daily was compared with biphasic insulin aspart, in which HbA$_{1c}$ levels were reduced by 1.04% vs 0.89%, respectively. In these comparisons of insulin and exenatide, exenatide reduced postprandial glucose more effectively, whereas insulin produced greater reductions in fasting plasma glucose. Bunc et al randomized 69 patients with T2D, already treated with metformin, to 12-months treatment with exenatide or once-daily insulin glargine. The dose of exenatide varied from 5 µg twice daily to 15 µg thrice daily. The reductions in HbA$_{1c}$ were in line with those in other studies (0.8% and 0.7%, respectively), as were reductions in fasting plasma glucose (1.6 and 2.9 mmol/L, respectively). At the end of the study period, both exenatide and insulin glargine were discontinued. Four weeks later, HbA$_{1c}$ and fasting plasma glucose had returned to pretreatment levels, indicating that continuous treatment with exenatide is required to maintain its efficacy. Data from an open-label extension to 3 double-blinded, placebo-controlled trials including 217 patients, with a mean body mass index (BMI) of 34 kg/m$^2$, receiving treatment with exenatide over a period of 3 years have also been reported. A mean reduction of 1.0% in HbA$_{1c}$ was preserved for up to 3 years. Finally, in a study of 235 overweight patients inadequately controlled on 2 or 3 oral hypoglycemic agents and randomized to add-on exenatide or insulin glargine, similar mean HbA$_{1c}$ reductions of -1.25 and -1.26%, respectively, were observed. However, 53.4% of exenatide-treated patients reached the composite end point of HbA$_{1c}$<7% and weight gain <1 kg, compared with just 19.8% of the insulin glargine-treated group.

The rates of hypoglycemia observed with exenatide treatment are largely dependent on the drugs with which it is combined. When exenatide was used alone, there were low rates of mild hypoglycemia (4%–5% and not significantly different from placebo), and no severe hypoglycemic events were reported. When exenatide was used in combination with metformin or in combination with both metformin and thiazolidinedione, there were also no increased risks of hypoglycemia. However, when it was combined with sulfonylurea (either alone or with metformin), there was an increase in the risk of mild to moderate hypoglycemia compared with placebo. There was only one incident of severe hypoglycemia in a patient treated with exenatide 5 µg and sulfonylurea that required assistance from a third person. The incidence of hypoglycemia was similar when once-daily insulin glargine was compared with twice-daily exenatide 10 µg. Most incidences of hypoglycemia were mild or moderate, but there were 4 episodes of major hypoglycemia in each group. Hypoglycemia was more common in those patients achieving a lower target level of HbA$_{1c}$<7% (61%
with exenatide and 68% with insulin glargine). Nocturnal hypoglycemia was also more common in the insulin glargine-treated group, while daytime hypoglycemia was more common in the exenatide-treated group. Similar findings were reported in the study of Davies et al.\textsuperscript{38} Although the occurrence of hypoglycemia may reflect an overall reduction in glucose levels that predisposes patients to a greater risk of hypoglycemia from concomitant administration of sulfonylureas, in vitro studies have shown that GLP-1 augments the insulin-releasing action of sulfonylureas.\textsuperscript{40} Therefore, the combination of a GLP-1 receptor agonist and sulfonylurea may be intrinsically more likely to result in hypoglycemia because of the closely related mechanism of action of these 2 classes of drugs.

Antibodies to exenatide were detected in approximately 40%-50% of patients receiving exenatide in phase III trials.\textsuperscript{28-30} The presence of antibodies appears to have no correlation with drug action, glycemic control, or adverse effects. Although the most common adverse effects are gastrointestinal (nausea, vomiting, and abdominal discomfort), exenatide is generally well tolerated. The gastrointestinal side effects were generally mild to moderate and tended to decrease with duration of treatment. Slow titration of exenatide also has been shown to reduce the rate of gastrointestinal side effects.\textsuperscript{41} The percentage of withdrawals attributed to nausea was low. The principal clinical trials of exenatide in patients with T2D are summarized in Table 1.

Exenatide has also been studied in combination with insulin, although this use currently remains off license. In an observational study of 134 patients treated with exenatide and insulin for at least 12 months, the addition of exenatide was associated with 45% discontinuation of soluble insulin, an average 9 units of reduction in soluble insulin doses, reduction in numbers of insulin injections from 2 to 1, and 59% discontinuation of sulfonylurea treatment. Despite these treatment reductions, there was a mean reduction of 0.87% in HbA\textsubscript{1c}.\textsuperscript{42} In another retrospective observational study of 268 patients treated with both exenatide and insulin for up to 27 months, mean reductions in HbA\textsubscript{1c} were around −55%, with reductions in soluble insulin doses of up to 55%.\textsuperscript{43}

Liraglutide

Early randomized controlled studies using liraglutide at low doses in patients with T2D found that this drug was well tolerated, at least as effective as metformin, and was not associated with weight gain.\textsuperscript{44,45} The efficacy of the drug was confirmed in a randomized, placebo-controlled, dose-ranging study of 5 weeks duration. Liraglutide alone reduced HbA\textsubscript{1c} by 0.8%, fasting plasma glucose by 3.9 mmol/L, and body weight by 2.2 kg compared with the combination of liraglutide and metformin. In addition, the combination therapy of liraglutide and metformin vs metformin and glimepiride significantly reduced the fasting glucose by 1.2 mmol/L.\textsuperscript{46} In another study of 14 weeks duration, liraglutide exhibited a dose-dependent decrease of HbA\textsubscript{1c}, and increased the proportion of patients achieving good glycemic control.\textsuperscript{47}

The role of liraglutide in the treatment of diabetes has been further defined in a programme of large scale, longer-duration clinical studies initiated by the manufacturers. This programme, known as the “Liraglutide Effect and Action in Diabetes” (LEAD) programme, has compared liraglutide with existing oral hypoglycemic therapies, as a single agent and in combinations. These trials are summarized in Table 2. LEAD 3 compared liraglutide with sulfonylurea glimepiride. In LEAD 1, 2, and 4 studies, liraglutide was added to other oral hypoglycemic agents. In LEAD 5, liraglutide and insulin glargine were compared as add-on therapy with metformin and glimepiride. Finally, LEAD 6 compared the addition of liraglutide or exenatide to treatment with metformin and/or glimepiride. These trials were all well-designed, controlled studies with a priori power calculations. Generally, follow-up and ascertainment of outcomes were well conducted, and apart from the LEAD 3 study,\textsuperscript{48} drop-out rates were low.

In the LEAD study programme, reductions in HbA\textsubscript{1c} with addition of liraglutide ranged between 0.8%-1.5% at 1.2 and 1.8 mg doses, and liraglutide appeared somewhat more effective in patients who had previously received monotherapy rather than combination therapy.\textsuperscript{49,50} The proportion of patients achieving glycemic targets with liraglutide was also consistently higher than that in the comparison groups. Notably, the LEAD 6 is the only study so far to compare liraglutide and exenatide. This 26-week trial randomized 233 patients to liraglutide 1.8 mg daily and 231 to exenatide 10 µg twice daily. The mean BMI of these patients was approximately 33 kg/m\textsuperscript{2} and mean HbA\textsubscript{1c} at baseline was 8.2%. The patients were already treated with metformin, sulfonylurea, or both. Liraglutide lowered mean HbA\textsubscript{1c} by 1.12% compared with 0.79% with exenatide, which gave a significant treatment difference. About 54% of liraglutide-treated patients achieved HbA\textsubscript{1c} < 7% compared with 43% of exenatide-treated group. Fasting blood glucose level was lower with liraglutide, but postprandial blood glucose level was higher.\textsuperscript{51} Overall, this study suggested a small but significant benefit of liraglutide over exenatide.
### Table 1 The principal clinical trials reviewed on exenatide in patients with type 2 diabetes

<table>
<thead>
<tr>
<th>Author + year</th>
<th>Baseline treatment</th>
<th>Interventions compared</th>
<th>No. of patients (% of dropouts)</th>
<th>Design</th>
<th>Duration, wk</th>
<th>Baseline BMI</th>
<th>Baseline HbA&lt;sub&gt;1c&lt;/sub&gt; %</th>
<th>Baseline FPG, mmol/L</th>
<th>∆ HbA&lt;sub&gt;1c&lt;/sub&gt;, %</th>
<th>∆ Weight, kg</th>
<th>∆ FPG, mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buse 2004&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Sulfonylurea</td>
<td>Addition of exenatide 5 µg BD, 10 µg BD vs placebo</td>
<td>377 (31%)</td>
<td>RCT, DB, PC</td>
<td>30</td>
<td>8.6</td>
<td>33.6</td>
<td>10.3</td>
<td>Exenatide 5 µg, −0.46%; exenatide 10 µg, −0.82%; placebo +0.12%</td>
<td>Exenatide 5 µg, −0.9 kg; exenatide 10 µg, −1.6 kg; placebo −0.6 kg</td>
<td>Exenatide 5 µg, −0.9; exenatide 10 µg, −1.6; placebo −0.6 mmol/L</td>
</tr>
<tr>
<td>DeFronzo 2005&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Metformin</td>
<td>Addition of exenatide 5 µg BD, 10 µg BD vs placebo</td>
<td>336 (19%)</td>
<td>RCT, DB, PC</td>
<td>30</td>
<td>8.2</td>
<td>34.2</td>
<td>9.5</td>
<td>Exenatide 5 µg, −0.4%; exenatide 10 µg, −0.8%; placebo +0.1%</td>
<td>Exenatide 5 µg, −1.6 kg; exenatide 10 µg, −2.8 kg; placebo −0.3 kg</td>
<td>Exenatide 5 µg, −0.4; exenatide 10 µg, −0.6; placebo +0.8 mmol/L</td>
</tr>
<tr>
<td>Kendall 2005&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Metformin and sulfonylurea</td>
<td>Addition of exenatide 5 µg BD, 10 µg BD vs placebo</td>
<td>733 (19%)</td>
<td>RCT, DB, PC</td>
<td>30</td>
<td>8.5</td>
<td>33</td>
<td>10.0</td>
<td>Exenatide 5 µg, −0.6%; exenatide 10 µg, −0.8%; placebo +0.2%</td>
<td>Exenatide 5 µg, −1.6 kg; exenatide 10 µg, −2.8 kg; placebo −0.3 kg</td>
<td>Exenatide 5 µg, −0.6; exenatide 10 µg, −0.6; placebo +0.8 mmol/L</td>
</tr>
<tr>
<td>Heine 2005&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Metformin and sulfonylurea</td>
<td>Addition of exenatide 10 µg BD vs insulin glargine</td>
<td>551 (15%)</td>
<td>RCT</td>
<td>26</td>
<td>8.2</td>
<td>31.4</td>
<td>10.2</td>
<td>Exenatide −1.1%; insulin glargine −1.1%</td>
<td>Exenatide −2.3 kg; insulin glargine +1.8 kg</td>
<td>Exenatide −1.4; insulin glargine −2.9 mmol/L</td>
</tr>
<tr>
<td>Nauck 2007&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Metformin and sulfonylurea</td>
<td>Addition of Exenatide 10 µg BD or biphasic aspart insulin</td>
<td>501 (16.6%)</td>
<td>RCT</td>
<td>52</td>
<td>8.6</td>
<td>30.3</td>
<td>11.2</td>
<td>Exenatide −1.04%; insulin −0.89%</td>
<td>Exenatide −2.5 kg; insulin +2.9 kg</td>
<td>Exenatide −1.8; insulin −1.7 mmol/L</td>
</tr>
<tr>
<td>Zinman 2007&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Pioglitazone 30 mg or rosiglitazone 4 mg ± metformin</td>
<td>Addition of exenatide 10 µg or placebo</td>
<td>232 (9%)</td>
<td>RCT, DB, PC</td>
<td>16</td>
<td>7.9</td>
<td>34</td>
<td>8.9</td>
<td>Exenatide −0.9%; placebo +0.1%</td>
<td>Exenatide −1.75 kg; placebo −0.24 kg</td>
<td>Exenatide −1.6; placebo +0.1 mmol/L</td>
</tr>
<tr>
<td>Barnett 2007&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Metformin or sulfonylurea</td>
<td>Addition of exenatide 10 µg BD or insulin glargine (crossover design)</td>
<td>138</td>
<td>RCT</td>
<td>32</td>
<td>8.95</td>
<td>31.1</td>
<td>12.0</td>
<td>Exenatide vs glargine −2.2 kg difference</td>
<td>Exenatide −2.9; glargine −4.1 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Moretto 2008&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Nil</td>
<td>Exenatide 5 µg BD, 10 µg BD vs placebo</td>
<td>232</td>
<td>RCT, DB, PC</td>
<td>24</td>
<td>7.8</td>
<td>31</td>
<td>Exenatide 5 µg, −0.7%; exenatide 10 µg, −0.9%; placebo −0.2%</td>
<td>Exenatide −2.8 kg; exenatide 10 µg, −3.1 kg; placebo −1.4 kg</td>
<td>Exenatide −2.8 kg; exenatide 10 µg, −3.1 kg; placebo −0.3 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Davies 2009&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Either 2 or 3 of metformin, sulfonylurea or thiazolidinedione</td>
<td>Exenatide 10 µg BD or insulin glargine as add-on</td>
<td>234 (13%)</td>
<td>RCT</td>
<td>26</td>
<td>8.57</td>
<td>34.1</td>
<td>10.48</td>
<td>Exenatide −1.25%; glargine −1.26%</td>
<td>Exenatide −2.73 kg; glargine −2.98 kg</td>
<td>Exenatide −2.12; glargine −2.61 mmol/L</td>
</tr>
<tr>
<td>DeFronzo 2010&lt;sup&gt;22&lt;/sup&gt;</td>
<td>Metformin</td>
<td>Exenatide 10 µg BD vs rosiglitazone 4 mg BD vs combination therapy</td>
<td>137 (26%)</td>
<td>RCT</td>
<td>20</td>
<td>7.8</td>
<td>32.5</td>
<td>8.4</td>
<td>Exenatide −0.9%; rosi −1.0%; combination therapy −1.3%</td>
<td>Exenatide −2.8 kg; rosi +1.5 kg; combination therapy −1.2 kg</td>
<td>Exenatide −1.46; rosi −1.8; combination therapy −1.6 mmol/L</td>
</tr>
</tbody>
</table>

**Note:** Changes in HbA<sub>1c</sub>, body weight, and fasting plasma glucose were all statistically significant.

**Abbreviations:** RCT, randomized controlled trial; DB, double blind; PC, placebo controlled; FPG, fasting plasma glucose.
<table>
<thead>
<tr>
<th>Author + year</th>
<th>Baseline treatment</th>
<th>Interventions compared</th>
<th>No. of patients (% of dropouts)</th>
<th>Design</th>
<th>Duration weeks</th>
<th>Baseline HbA1c %</th>
<th>Baseline BMI</th>
<th>Baseline FPG, mmol/L</th>
<th>∆ HbA1c %</th>
<th>∆ Weight, kg</th>
<th>∆ FPG, mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marre 200950</td>
<td>Glimepiride</td>
<td>Addition of liraglutide (3 doses), rosiglitazone or placebo</td>
<td>1041 (14.7%)</td>
<td>RCT, DB, PC</td>
<td>26</td>
<td>8.5%</td>
<td>30</td>
<td>10</td>
<td>Liraglutide −1.6 vs placebo</td>
<td>Liraglutide −2.1 kg; liraglutide (1.8 mg), −0.2 kg</td>
<td>Liraglutide 1.2 mg, and 1.8 mg, −2.6 kg vs placebo</td>
</tr>
<tr>
<td>Nauck 2009</td>
<td>Metformin</td>
<td>Addition of liraglutide (3 doses), glimepiride or placebo</td>
<td>1091 (6.7%)</td>
<td>RCT, DB, PC</td>
<td>26</td>
<td>8.4%</td>
<td>31</td>
<td>10</td>
<td>Liraglutide 0.6 mg, −0.7%; 1.2 mg, −1.0% and 1.2 mg, 1.8 mg, −1.0% and −2.6 kg; 1.8 mg, −2.8 kg; glimepiride −1.0%; placebo +0.1%</td>
<td>Liraglutide 0.6 mg, −1.1; 1.2 mg, −1.6; 1.8 mg, −1.7; glimepiride −1.3; placebo +0.4 mmol/L</td>
<td></td>
</tr>
<tr>
<td>Garber 2008</td>
<td>Various oral agents</td>
<td>Previous treatments withdrawn subjects randomized to liraglutide 1.2 mg or 1.8 mg or glimepiride</td>
<td>746 (43%)</td>
<td>RCT, DB</td>
<td>52</td>
<td>8.3%</td>
<td>33</td>
<td>9.3–9.5</td>
<td>Liraglutide 1.2 mg, −0.84%; 1.8 mg, −1.14%; glimepiride −0.51%</td>
<td>Liraglutide 1.2 mg, −2.0 kg; 1.8 mg, −2.5 kg; glimepiride +1.0 kg; placebo −1.5 kg</td>
<td>Liraglutide 1.2 mg, −0.84; 1.8 mg, −1.42; glimepiride −0.29 mmol/L</td>
</tr>
<tr>
<td>Zinman 200924</td>
<td>Metformin + rosiglitazone</td>
<td>Addition of liraglutide 1.2 mg or 1.8 mg or glimepiride</td>
<td>533</td>
<td>RCT, DB, PC</td>
<td>26</td>
<td>8.4–8.6</td>
<td>33</td>
<td>10</td>
<td>Liraglutide both doses −1.5% vs placebo group −0.5% in placebo group</td>
<td>Liraglutide 1.8 mg, −2.0 kg; 1.2 mg, −1.0 kg; placebo +0.6 kg</td>
<td>Liraglutide 1.2 mg, −2.2; 1.8 mg, −2.4; placebo −0.4 mmol/L</td>
</tr>
<tr>
<td>Russell-Jones 200923</td>
<td>Metformin and glimepiride</td>
<td>Addition of liraglutide 1.8 mg or placebo or insulin glargine</td>
<td>581 (11%)</td>
<td>RCT, PC</td>
<td>26</td>
<td>8.3%</td>
<td>30</td>
<td>9.1–9.4</td>
<td>Liraglutide −1.33%; glargine −0.42 kg; placebo +1.6 kg</td>
<td>Liraglutide −1.8 kg; glargine −0.42 kg; placebo +1.6 kg</td>
<td>Liraglutide −1.55; glargine −1.79; placebo −0.53 mmol/L</td>
</tr>
<tr>
<td>Buse 200951</td>
<td>Metformin or/and Sulfonylurea</td>
<td>Addition of liraglutide or exenatide</td>
<td>464 (16.8%)</td>
<td>RCT</td>
<td>26</td>
<td>8.2%</td>
<td>33</td>
<td>9.5–9.8</td>
<td>Liraglutide −1.12%; exenatide −0.79%</td>
<td>Liraglutide −3.24 kg; exenatide −2.87 kg</td>
<td>Liraglutide −1.61; exenatide −0.60 mmol/L</td>
</tr>
</tbody>
</table>

Note: Changes in HbA1c, body weight, and fasting plasma glucose were all statistically significant.

Abbreviations: RCT, randomized controlled trial; DB, double blind; PC, placebo controlled; FPG, fasting plasma glucose.
In LEAD 3 and LEAD 2, the rates of minor hypoglycemia were significantly lower in liraglutide-treated group than in glimepiride-treated groups, and no major hypoglycemic events were recorded in these studies. In LEAD 1, in which the baseline treatment was with sulfonylurea, minor hypoglycemia was more frequent with liraglutide add-on treatment compared with rosiglitazone add-on treatment. In LEAD 4, the rate of minor hypoglycemia was also higher with liraglutide than with placebo, although no serious hypoglycemia was observed. In LEAD 5, the frequency of minor hypoglycemia was similar with both insulin glargine and liraglutide, although 5 patients treated with liraglutide reported major hypoglycemic events. Finally, in LEAD 6, liraglutide was associated with fewer minor hypoglycemic events than exenatide, and 2 patients receiving treatment with exenatide and sulfonylurea experienced major hypoglycemia. In patients receiving liraglutide in addition to metformin or rosiglitazone, the risk of hypoglycemia was very low. Thus, the risk of hypoglycemia with GLP receptor agonists appears higher in specific combination therapy with sulfonylureas.

The most frequent adverse effects are gastrointestinal intolerance, especially nausea. However, this subsides soon in most patients. In LEAD 6, liraglutide and exenatide produced similar initial rates of nausea, although by the end of the study, there was a significantly greater rate of nausea in the exenatide-treated group. Although adverse event rates were low, the liraglutide group reported slightly more serious and severe adverse events than the exenatide group. Six cases of pancreatitis were also reported during the LEAD programme, and all but 5 were in liraglutide-treated patients. In LEAD 6, although there was 1 episode of mild pancreatitis in the liraglutide-treated group, liraglutide treatment was continued in that patient. However, a recent commentary on this subject draws attention to 7 reported cases of pancreatitis out of 4,257 patients treated in phase II and III trials of liraglutide compared with just 1 case of pancreatitis in the 2,381 patients who received comparator treatments. After adjustment for patient-years of exposure to liraglutide, this study represented a 4-to-1 imbalance between the liraglutide and comparator groups. Therefore, although there may be a small risk of pancreatitis, the number of patients affected is small, and so the magnitude of this risk is difficult to determine.

The long-term treatment of rodents with liraglutide was found to cause thyroid C-cell hyperplasia, which raised the concerns that long-acting GLP-1 agonists might carry an increased risk of medullary thyroid cancer. Although the primate C-cells are apparently much less sensitive to GLP-1 receptor agonists, and this highlights the need for long-term postmarketing surveillance of new classes of drugs.

**Effects on body weight**

**Exenatide**

Exenatide has consistently caused significant weight loss in a range of clinical trials. These effects are summarized in Table 1. As a GLP-1 receptor agonist, exenatide also has a variety of nonglycemic effects on appetite and gastric emptying. Three placebo-controlled trials have demonstrated significant dose-dependent weight loss with exenatide compared with placebo. When exenatide was added to sulfonylurea therapy alone, there was a weight loss of 1.6 kg in the 10-µg dose group compared with 0.6 kg weight loss in the placebo group. When exenatide at doses of 10 and 5 µg was added to metformin and sulfonylurea, it elicited the weight loss of 1.6 kg in both groups compared with 0.9 kg in the placebo group. Exenatide added to metformin alone caused the greatest weight reduction of 1.6 and 2.8 kg at the 5 and 10 µg doses, respectively. Similar weight reduction was observed with exenatide at 10-µg dose in patients treated with a combination of rosiglitazone or pioglitazone with or without metformin, with an average weight loss of 1.74 kg over 32 weeks. In another randomized study, exenatide 10 µg twice daily combined with rosiglitazone 4 mg elicited average weight loss of 1.2 kg in contrast to the weight gain of 1.5 kg with rosiglitazone alone and weight loss of 2.8 kg with exenatide alone.

In the open-label extension of the 3 phase III clinical trials of exenatide, there was a progressive weight loss in those treated with exenatide 10 µg for 3 years. Although this was an uncontrolled trial, in 217 subjects, the mean weight loss was 5.3 kg at 3 years. In a 30-week study, mean weight loss was 3.0 kg, whereas this also reached 5.3 kg after 82 weeks. Therefore, weight loss with exenatide may reach a plateau after about 18 months. In these studies, weight loss with exenatide was apparently independent of gastrointestinal side effects.

Exenatide as monotherapy in drug-naive patients with T2D has also shown significant weight loss. After 24 weeks of treatment with exenatide 5 µg, 10 µg, or placebo, mean weight loss was 2.8, 3.1, or 1.4 kg, respectively. In open-label comparisons of exenatide, insulin glargine, and biphasic insulin aspart, the value of exenatide as an adjunctive therapy was highlighted. Although these 3 therapies improved glycemic control comparable extents, exenatide was associated with significant weight loss, whereas insulin leads to weight gain. When insulin glargine was added to metformin
and sulfonylurea, the weight gain was 1.8 kg compared with weight loss of 2.3 kg in the exenatide-treated patients. After 1 year of treatment with biphasic insulin aspart, the weight gain was 2.9 kg compared with weight loss of 2.5 kg with exenatide. In another study, add-on treatment with exenatide resulted in 2.73 kg of weight loss compared with 2.98 kg weight gain in the glargine-treated group, an overall difference of 5.71 kg. Interestingly, exenatide also evoked average weight losses of 5.2 kg and 5.5 kg when used in combination with insulin. Finally, in a small open-label trial in women with polycystic ovary syndrome, the effect of treatment with metformin alone, exenatide alone, or the combination of both on the menstrual regularity and weight was evaluated. Metformin alone led to the weight loss of 1.6 kg, exenatide alone to 3.2 kg, and the combination of both to 6 kg. Otherwise, there are only limited published data on the use of exenatide in patients with nondiabetic obesity.

**Liraglutide**

The beneficial effect of liraglutide on body weight was observed in all the early studies of this drug, and significant dose-dependent weight loss was demonstrated in all of the LEAD studies. In the monotherapy study (LEAD 3), absolute weight loss was 2.5 kg at the 1.8 mg dose and 2.1 kg at the 1.2 mg dose. Weight loss was greatest in combination with metformin: 2.8 kg with the 1.8 mg dose and 2.6 kg with the 1.2 mg dose. In LEAD 1, the addition of liraglutide to sulfonylurea abolished the weight gain observed in the group treated with the combination of sulfonylurea and rosiglitazone. In combination with metformin and rosiglitazone, weight loss was 2 kg at the 1.8 mg dose and 1 kg at the 1.2 mg dose. In LEAD 5, treatment with insulin glargine increased weight by 1.6 kg, whereas liraglutide decreased weight by 1.8 kg. In LEAD 6, at the 1.8 mg dose, liraglutide elicited weight loss of 3.2 kg compared with 2.9 kg in the exenatide group. The reduction of body weight with liraglutide is confirmed to result from a reduction in body fat. Therefore, liraglutide-induced weight loss is maximal in metformin-treated patients, but liraglutide appears to offset the weight gain that often results from treatment with sulfonylurea, thiazolidinediones, or insulin. These effects on body weight are summarized in Table 2.

A potential role of liraglutide as a weight loss treatment is emerging. In a recently reported trial of 20 weeks duration, 564 obese individuals with BMI 30–40 kg/m² were randomly assigned to any one of 4 doses of liraglutide (1.2, 1.8, 2.4, or 3.0 mg), placebo, or orlistat. All subjects were advised for a 500-calorie energy-deficit diet and to increase physical activity. Subjects on liraglutide lost significantly more weight than did those on placebo or orlistat. Mean weight loss with these 4 doses of liraglutide was 4.8, 5.5, 6.3, and 7.2 kg vs 2.8 kg in the placebo group and 4.1 kg in the orlistat group. About 76% of individuals lost more than 5% weight with liraglutide 3.0 mg compared with 30% in the placebo or 44% in the orlistat groups. Liraglutide reduced blood pressure at all doses and improved glucose tolerance. Although transient nausea was the commonest adverse effect, liraglutide was generally well tolerated at these higher doses. Therefore, liraglutide is a promising drug for weight loss. All these observations are more important in view of the withdrawal of rimonabant and sibutramine, which has severely restricted the current choice of drugs for weight loss.

**Effects on blood pressure**

An unexpected but consistent effect of liraglutide in the LEAD programme was the modest reduction of blood pressure, ranging from 2.1 to 6.7 mm Hg. GLP-1 has been reported to have a natriuretic effect, which might explain its effect on blood pressure. In contrast, a recently reported randomized, controlled trial in patients treated with metformin and/or thiazolidinedione compared the effect of exenatide or placebo on ambulatory blood pressure. However, although a nonsignificant trend was suggested, no reduction of blood pressure was observed with exenatide. However, in a pooled analysis of data from 6 trials involving 2,171 patients, systolic blood pressure was reduced in the exenatide-treated groups by 2.8 mm Hg when compared with placebo and by 3.7 mm Hg when compared with insulin-treated patients, but no effect was observed on diastolic blood pressure. The reduction in blood pressure appeared highest in patients with systolic blood pressure of >150 mm Hg. A weak correlation between weight loss and blood pressure reduction was also observed. Vasorelaxant effects of GLP-1 have been observed in various animal and in vitro studies, and infusion of GLP-1 in humans with T2D leads to increased flow-mediated vasodilatation in the brachial artery. Therefore, GLP-1 and GLP-1 receptor agonists appear to possess the useful additional property of reducing blood pressure. Furthermore, one may speculate that reduced GLP-1 secretion could be a factor contributing to the increased prevalence of hypertension among patients with T2D.

**Conclusions**

GLP-1 receptor agonists are one of the most significant recent advances in the treatment of T2D. Although weight loss is
regularly identified as a treatment priority for patients with T2D, it is ironic that many patients find that the established pharmacological approaches to treatment with sulfonylureas, thiazolidinediones, and insulin only improve glycemic control at the cost of significant weight gain. GLP-1 receptor agonists have rapidly established a place as add-on therapy to other oral agents, in preference to a direct move onto insulin treatment. Clearly, long-term studies will be required to compare these strategies. GLP-1 receptor agonists also seem to have a significant potential as weight loss drugs in persons both with and without T2D; however, in view of the historical problems with weight loss drugs, it is important to demonstrate their long-term safety and efficacy in this role. Because prevention of cardiovascular disease is an important objective in treating patients with T2D, it is now essential to demonstrate the apparently favorable short-term effects of GLP-1 receptor agonists on glycemic control and weight observed in clinical trials to date translate into safe and effective long-term reductions of diabetes-related cardiovascular events and other relevant clinical end points.

Liraglutide and exenatide differ in several respects, and these differences are likely to influence clinical choices. The once-daily dosage of liraglutide makes this drug more appealing than exenatide for a group of patients who are often already receiving many different medicines. The convenience of being able to take liraglutide at any time of the day, irrespective of meal times, is also attractive. The LEAD 6 study suggests that liraglutide is somewhat more effective than exenatide in lowering the blood glucose and HbA1c levels. Both drugs are relatively well tolerated, and serious hypoglycemia is very unusual; nevertheless, liraglutide may be less liable to cause hypoglycemia. Liraglutide also consistently reduces blood pressures, whereas this effect may be less marked or absent with exenatide. Compared with exenatide, the absence of allergy to liraglutide, which is largely homologous with human GLP-1, also favors liraglutide. Pharmacokinetic considerations suggest that there may be less risk of drug accumulation with liraglutide compared with exenatide, so that liraglutide might be tolerated better by patients with diabetic nephropathy. However, we were unable to identify any additional reports on patients with advanced nephropathy. Although both liraglutide and exenatide induce gastrointestinal side effects, this effect is of significantly shorter duration with liraglutide, enabling more patients to continue the drug. Finally, while both drugs clearly elicit weight loss, which is highly desirable for all patients with T2D, the observation that liraglutide is significantly more effective than orlistat in a randomized, controlled trial may also make this drug an important treatment choice for many patients. Thus, GLP-1 receptor agonists are becoming favorable alternative to the existing hypoglycemic therapies that are of modest efficacy and usually result in weight gain.

Currently, several considerations appear to favor the selection of liraglutide over exenatide. However, the development of new long-acting formulations such as once-weekly exenatide, which was more effective in lowering HbA1c than exenatide administered twice daily,68 clearly has the potential to influence this choice. Several new GLP-1 receptor agonists, including agents that may be taken orally, are also in development, and it remains to be seen how such drugs will compare with the existing 2 agents.

Disclosure
The authors report no conflicts of interest in this work.

References


---

Therapeutics and Clinical Risk Management
Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.